# Precise Neoadjuvant Chemoresection of Low Grade NMIBC

> **NCT06227065** · PHASE2 · NOT_YET_RECRUITING · sponsor: **University of Bern** · enrollment: 28 (estimated)

## Conditions studied

- Bladder Cancer
- Non-muscle Invasive Bladder Cancer
- Low-risk

## Interventions

- **DRUG:** Epirubicin
- **DRUG:** Mitomycin
- **DRUG:** Gemcitabine
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT06227065
- **Lead sponsor:** University of Bern
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-10
- **Primary completion:** 2026-10
- **Final completion:** 2029-10
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2024-01-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06227065

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06227065, "Precise Neoadjuvant Chemoresection of Low Grade NMIBC". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT06227065. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*